Immune globulin - Takeda
Alternative Names: 10% HyQ; 20% SubQ; CUVITRU; Cuvitru; Gammagard Liquid; Gammagard S/D; Human Immune Globulin for Subcutaneous Administration; HyQ; HYQVIA; HyQvia; Ig20Gly;… See moreLatest Information Update: 03 Jan 2025
Price :
$50 *
At a glance
- Originator Baxter International
- Developer Baxter International; Halozyme Therapeutics; Shire; Takeda
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allotransplant rejection; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
- Registered Agammaglobulinaemia; Chronic inflammatory demyelinating polyradiculoneuropathy
- Phase II Ataxia
- Discontinued Alzheimer's disease
Most Recent Events
- 30 Dec 2024 Japanese Ministry of Health, Labour and Welfare (MHLW) approves immune globulin infusion 10% with ENHANZE® for patients with Agammaglobulinemia (SC, Injection)
- 24 Dec 2024 Takeda plans a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy (SC, Infusion) in January 2025 (NCT06747351)
- 01 Aug 2024 Preregistration for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (IV)